Objective: To clarify the efficacy of Prostate Health Index (phi) for clinical use in the office urology.
Methods: For 147 patients with prostate specific antigen (PSA) in the gray zone, phi was measured additionally and the correlation was studied between phi and other conventional biomarkers, including of PSA, free-PSA/total-PSA (F/T PSA) and PSA/volume of the prostate (PSAD). And among 30 patients who were pathologically diagnosed, the accuracy of each biomarker was studied using the findings of digital rectal examination (DRE), ultrasound (US), and MRI.
Results: phi had a weak correlation with PSA, PSAD, and a weak negative correlation with F/T PSA. In 30 biopsied patients (12 patients with cancer and 18 patients with no cancer), sensitivity, specificity, positive predictive value and negative predictive value of phi with a cutoff level of 27.2 were 91.7%, 27.8%, 45.8% and 83.3% respectively. Those of PSAD were 66.7%, 27.8%, 38.1%, and 55.6%, while those of F/T PSA were also 66.7%, 27.8, 38.1%, and 55.6 respectively. The diagnostic accuracy was improved by phi. In a group of 15 biopsies-patients with no remarkable finding of DRE, US and MRI, sensitivity and specificity of phi were 100% and 36.4% and this group benefit most from the effectiveness of phi.
Conclusion:: The diagnostic accuracy of phi was superior to those of PSAD and F/T PSA in the PSA gray zone cases. In addition, clinical findings, including US and MRI, indicated that phi could be more effective.
View full abstract